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Abstract: Six new sterols (1–6), together with seven known sterols (7–13), were isolated 
from the CCl4 extract of the marine bryozoan Cryptosula pallasiana, four (3–6) of which 
have already been reported as synthetic sterols. This is the first time that these compounds 
(3–6) are reported as natural sterols. The structures of the new compounds were determined 
on the basis of the extensive spectroscopic analysis, including two-dimensional (2D) NMR 
and HR-ESI-MS data. Compounds 1–4, 7 and 10–13 were evaluated for their cytotoxicity 
against HL-60 human  myeloid leukemia  cell line, and all of the evaluated compounds 
exhibited moderate cytotoxicity to HL-60 cells with a range of IC50 values from 14.73 to 
22.11 µg/mL except for compounds 12 and 13. 
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1. Introduction  
Marine  bryozoans  are  well  known  producers  of  bioactive  secondary  metabolites  and  important 
marine drug sources due to their remarkable antineoplastic activity [1]. Bryostatins isolated from the 
marine  bryozoans  Bugula  neritina  are  a  well  known  example  [2].  Other  bioactive  secondary 
metabolities  from  marine  bryozoans  include  alkaloids,  sterols,  as  well  as  heteratom-containing 
compounds, which showed remarkable activities on tumor cell lines,  such as  murine lymphocytic 
leukemia P388, human myeloid leukemia HL-60, human leukemia U937, human hepatocellular liver 
carcinoma HepG2, etc. [3–6]. In our previous studies focused on B. neritina, a new antineoplastic 
macrolide, bryostatin 19, two ceramides and four cerebrosides,  as well as a series of sterols were 
isolated from this bryozoan [5–8]. In the course of our ongoing investigations toward the isolation of 
biologically  active  secondary  metabolites  from  marine  bryozoans,  Cryptosula  pallasiana  was 
investigated, another genus of marine bryozoans, collected from the coast of Huang Island in Qingdao 
City, Shandong Province of China. Herein, we report the isolation and structure identification of six 
new sterols (1–6) and seven known sterols (7–13), four (3–6) of which have already been reported as 
synthetic sterols [9–11]. This  is the first time that  these compounds (3–6) are reported as  natural 
sterols. In addition, the cytotoxicity of the oxygenated sterols 1–4, 7 and 10–13 against HL-60 human 
myeloid leukemia cell line is also described. 
Figure 1. Chemical structures of compounds 1–13 from the marine bryozoan Cryptosula 
pallasiana. 
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2. Results and Discussion 
The CCl4 extract (12.9 g) of the marine bryozoan C. pallasiana was fractionated by Sephadex  
LH-20 chromatography to afford three major fractions (Frs. A–C). Fr. A (5.66 g) was further subjected 
to column chromatography (CC) over reversed-phase silica gel column (RP-18) and normal silica gel 
column, respectively, and then further purified by reverse semi-preparation HPLC to yield compounds 
1–13 (Figure 1). 
Table 1. 
1H NMR (500 MHz) and 
13C NMR (125 MHz) data of compounds 1 and 2 in CDCl3 
a. 
  1      2 
Position  c, mult.  H, (int., mult., J in Hz)    c, mult.  H, (int., mult., J in Hz) 
1  37.4 t  ʱ 1.84 (1H, m), β 1.14 (1H, m)    36.9 t  ʱ 1.82 (1H, m), β 1.16 (1H, m) 
2  31.8 t  ʱ 1.83 (1H, m), β 1.49 (1H, m)    31.6 t  ʱ 1.84 (1H, m), β 1.51 (1H, m) 
3  71.9 d  3.52 (1H, m)    71.6 d  3.61 (1H, m) 
4  42.4 t  ʱ 2.28 (1H, m), β 2.23 (1H, m)    42.5 t  ʱ 2.33 (1H, m), β 2.29 (1H, m) 
5  140.9 s  −    146.2 s  − 
6  121.8 d  5.35 (1H, t, 2.8)    120.9 d  5.73 (1H, dd, 5.0, 1.7) 
7  32.0 t  ʱ 1.48 (1H, m), β 1.97 (1H, m)    74.1 d  3.27 (1H, m) 
8  32.0 d  1.46 (1H, m)    37.3 d  1.50 (1H, m) 
9  50.2 d  0.93 (1H, m)    42.9 d  1.31 (1H, m) 
10  36.6 s  −    37.6 s  − 
11  21.2 t  ʱ 1.00 (1H, m), β 1.47 (1H, m)    20.9 t  ʱ 1.02 (1H, m), β 1.49 (1H, m) 
12  39.9 t  ʱ 1.15 (1H, m), β 1.99 (1H, m)    39.1 t  ʱ 1.19 (1H, m), β 1.94 (1H, dt, 12.6, 3.6) 
13  42.5 s  −    42.2 s  − 
14  56.9 d  0.98 (1H, m)    49.3 d  1.51 (1H, m) 
15  24.5 t  ʱ 1.59 (1H, m), β 1.08 (1H, m)    24.4 t  ʱ 1.59 (1H, m), β 1.07 (1H, m) 
16  28.4 t  ʱ 1.84 (1H, m), β 1.28 (1H, m)    28.8 t  ʱ 1.74 (1H, m), β 1.26 (1H, m) 
17  56.0 d  1.10 (1H, m)    55.8 d  1.21 (1H, m) 
18  12.1 q  0.69 (3H, s)    11.8 q  0.67 (3H, s) 
19  19.5 q  1.00 (3H, s)    18.4 q  0.98 (3H, s) 
20  36.2 d  1.47 (1H, m)    40.3 d  2.05 (1H, m) 
21  18.9 q  0.91 (3H, d, 6.6)    21.0 q  1.01 (3H, d, 6.6) 
22  39.3 t  a 2.17 (1H, m), b 1.78 (1H, m)    138.4 d  5.22 (1H, dd, 15.2, 8.1) 
23  128.8 d  5.50 (1H, m)    126.3 d  5.27 (1H, m) 
24  136.8 d  5.38 (1H, d, 15.8)    42.1 t  1.83 (2H, m) 
25  75.0 s  −    28.7 d  1.58 (1H, m) 
26  25.9 q  1.25 (3H, s)    22.4 q  0.86 (3H, d, 1.9) 
27  26.3 q  1.25 (3H, s)    22.5 q  0.83 (3H, d, 1.9) 
7−OCH3  −  −    56.9 q  3.35 (3H, s) 
25−OCH3  50.4 q  3.15 (3H, s)    −  − 
a Assignments aided by the DEPT, COSY, TOCSY, HSQC, HMBC, and NOESY experiments. Mar. Drugs 2011, 9                                                  
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Compound 1 was obtained as a white amorphous powder and was positive to Liebermann-Burchard 
test.  The  positive  ion  mode  HR-ESI-MS  spectrum  showed  a  pseudomolecular  ion  peak  at  m/z 
437.3398 [M + Na]
+ (C28H46O2Na, calculated for 437.3396), which, together with the molecular ion 
peak at m/z 414 [M]
+ in the positive ion mode EI-MS, enabled the determination of the molecular 
formula C28H46O2, with the help of NMR data (Table 1).  
An extensive examination of 
1H NMR and 
13C NMR spectra data, to draw assistance from the data 
of 
1H-
1H COSY, HSQC and HMBC spectra, allowed the establishment of a sterol skeleton with a  
5(6)-double bond (ʴC 140.9 and 121.8), which was consistent with the literature [12]. The 
1H NMR 
spectrum  showed  five  methyl  resonance  signals  at  ʴH  0.69  (3H,  s),  0.91  (3H,  d,  J  =  6.6  Hz),  
1.00 (3H, s),  and 1.25  (6H, s), which were  ascribed to the methyl  groups  18, 21, 19 and 26/27, 
respectively. The resonances at ʴH 3.52 (1H, m) and 5.35 (1H, t, J = 2.9 Hz) assigned for H-3 and the 
olefinic proton H-6, respectively, were indicative for Δ
5 mon-hydroxylated steroidal nucleus, which 
was confirmed by HMBC correlations from H-6 to C-4 (ʴC 42.4), C-7 (ʴC 32.0), C-8 (ʴC 32.0) and  
C-10 (ʴC 36.6) (Figure 2), as well as 
1H-
1H COSY correlations from H-3 to H2-2 and H2-4. The partial 
structure of C-17 side chain in compound 1 was established based on EI-MS, 1D and 2D NMR data. 
The double bond of C-23 (ʴC 128.8) and C-24 (ʴC 136.8) was confirmed by the cross peaks of H-23  
(ʴH 5.50, m) to C-22 (ʴC 39.3), C-24 and C-25 (ʴC 75.0); H-24 (ʴH 5.38, d, J = 15.8 Hz) to C-22 and  
C-23 in the HMBC spectrum, and was determined to be trans-disubstituted due to the large coupling 
constant  (J23,24  =  15.8  Hz).  The  methoxy  group  (ʴH  3.15  (3H,  s),  ʴC  50.4)  at  C-25  position  was 
confirmed by the HMBC spectrum data (Figure 2) and fragment ion at m/z 382 [M − OCH3 − H]
+  
in the EI-MS spectrum of 1. Based on the above analysis, the plane structure of 1 was determined 
(Figure 1).  
In the NOESY experiment, both H-3 and H-6 correlated with H-4ʱ (ʴH 2.28, m), indicating the  
β-orientation of the hydroxyl group on C-3 (Figure 2), which was confirmed by the chemical shift of 
C-3 (ʴC 71.9 > 70.0) [13]. After mapping all of the signals for each moiety by careful inspection of the 
1D and 2D NMR spectra, compound 1 was unambiguously assigned as (23E)-25-methoxy-cholesta-
5,23-dien-3β-ol. Sterol 1, not reported previously in the literature, is a new sterol with trans-double 
bonds between C-23 and C-24, together with a methoxy group at C-25 in the side chain. 
Figure 2. Key HMBC and NOESY correlations of compounds 1 and 2. 
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Compound 2 was isolated as an isomer of 1, due to the same formula of C28H46O2 from EI-MS  
(m/z 414 [M]
+) and HR-ESI-MS (m/z 437.3394 [M + Na]
+ (C28H46O2Na, calculated for 437.3396)), 
with the help of 1D NMR spectral data. Fragment at m/z 382 [M − OCH3 − H]
+ due to loss of a Mar. Drugs 2011, 9                                                  
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methoxy group, as well as the two ion fragments at m/z 271 [M − C8H15 − OCH3 − H]
+ and 253  
[M  −  C8H15  −  OCH3  −  H  −  H2O]
+,  suggested  the  presence  of  the  mono-hydroxylated  and  
mono-methoxylated steroid with a mono-unsaturated side chain. The presence of a strong peak in the 
EI-MS at m/z  111 confirmed the presence of the C8H15 side chain. The partial structure of a  Δ
22  
mono-unsaturated side chain was established from the HMBC spectrum of 2 (Figure 2), which showed 
correlations of H3-27/C-25, H3-26/C-25, H3-26/C-24, H-23/C-24, H-23/C-20, H-22/C-23, H-22/C-20, 
H3-21/C-17, H3-21/C-20 and H3-21/C-22. The position of the methoxy group was assigned as C-7  
(ʴC 74.1) due to a strong broad singlet at ʴH 3.35 (3H, s) correlated to C-7 in the HMBC spectrum, and 
the partial structure of the steroidal nucleus was confirmed by the observation of the HMBC cross 
peaks from H2-4 to C-3, C-5 and C-6; H-6 to C-4, C-8 and C-10; H3-18 to C-13, C-14 and C-17, and 
H3-19 to C-1 and C-10 (Figure 2). The configuration of the double bond between C-22 and C-23 was 
determined to be trans-disubstituted due to the large coupling constant (J22,23 = 15.2 Hz) between H-22 
and  H-23.  The  β-orientation  of  the  hydroxyl  group  on  C-3  was  deduced  also  from  the  NOESY 
correlations  of  H-3/H-4ʱ  and  H-4ʱ/H-6,  and  the  β-orientation  of  the  methoxy  group  on  C-7  was 
deduced  by  observation  of  correlations  of  H-7ʱ/H-6  and  H-7ʱ/H-14  in  the  NOESY  experiment  
(Figure 2). Accordingly, compound 2 can be defined as (22E)-7β-methoxy-cholesta-5,22-dien-3β-ol. 
Compound 3 was isolated as a white amorphous powder and was also positive to the Libermann-
Burchard test. Its molecular formula was established as C28H48O2 by observation of the molecular ion 
peak at m/z 439.3550 [M + Na]
+ (C28H48O2Na, calculated for 439.3552) in the HR-ESI-MS spectrum 
and ion peak at m/z 416 [M]
+ in the EI-MS spectrum. Comparison of the 
1H NMR and 
13C NMR 
spectra of 3 with those of 2 revealed that they shared the same 3β-hydroxy, 7β-methoxy Δ
5-steroid 
nucleus but differed in the side chain. Compound 3 was finally assigned as 7β-methoxy-cholest-5-en-
3β-ol due to the missing trans-double bonds between C-22 and C-23 in the 
13C NMR spectrum by 
comparison with 2. Compound 3 has been reported as a synthetic sterol with effective inhibition of 
cholesterol acyltransferase (ACAT) [9] and is reported here as a natural product for the first time. 
Compound 4 was obtained as a white amorphous powder and was positive to Liebermann-Burchard 
test.  The  HR-ESI-MS  spectrum  showed  the  molecular  ion  peak  at  m/z  407.2928  [M  +  Na]
+ 
(C26H40O2Na, calculated for 407.2926) and EI-MS spectrum showed the molecular ion peak at m/z 384 
[M]
+ corresponding to the molecular formula C26H40O2, with the help of NMR data. Compound 4 was 
assumed to have the same typical nucleus of 3β-hydroxy Δ
5-steroid by comparing the 1D NMR data 
with those of 1, but differed in the side chain. The protons of trans-olefinic bonds in the side chain 
appeared at ʴH 6.07 (1H, d, J = 15.5 Hz) and 6.78 (1H, m). The HSQC spectral data indicated that the 
proton  H-24  (ʴH  6.07)  was  connected  to  the  carbon  at  ʴC  132.8  (C-24)  and  H-23  (ʴH  6.78)  was 
connected to the carbon at ʴC 147.6 (C-23), while the protons H2-22 (ʴH 2.34, 1.98) were connected to 
the carbon at  ʴC 39.5 (C-22). The correlation of H-23  with H2-22 and H-24 in  the 
1H-
1H COSY 
spectrum indicated that the double bonds were in C-23 and C-24. This was also supported by the key 
cross-peaks H-24 with C-22 and H-23 with C-22 in the HMBC experiment. Similarly, the downfield 
singlet methyl protons at ʴH 2.25 (H3-26) exhibited HMBC correlations with C-25 (ʴC 198.7) and C-24, 
and upfield methyl proton signals at ʴH 0.95 (H3-21) with C-17 (ʴC 55.9), C-20 (ʴC 36.0) and C-22, 
suggesting the remnant connectivities of the side chain in compound 4. Accordingly, 4 was finally 
assigned as (23E)-3β-hydroxy-27-norcholesta-5,23-dien-25-one, which had been obtained by synthesis 
[10], but was reported as a natural product for the first time. Mar. Drugs 2011, 9                                                  
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Another two stereoisomeric sterols, 5 and 6, were isolated as white amorphous powder, and were 
analyzed  to  share  the  same  molecular  formula  of  C27H44O2  using  EI-MS  (m/z  400  [M]
+)  and  
HR-ESI-MS data. The 
1H NMR and
 13C NMR data of 5 and 6 agreed with those of cholesta-5,25-
diene-3β,24ξ-diol from red alga Galaxaura marginata [14]. Although, the configuration at C-24 was 
hard to determine due to the small difference in the chemical shift of C-24 in the 
13C NMR spectrum 
between S and R epimers (Table 2), compound 5 was finally assigned as 24(R)-cholesta-5,25-diene-
3β,24-diol due to no correlation between H-24 and H-20β in the NOESY experiment, whereas, the 
presence  of  H-24  correlated  with  H-20β  in  6  confirmed  the  correct  configuration  of  C-24  in  5. 
Furthermore, the results were confirmed by the 
1H NMR data of 5 and 6, consistent with the same 
synthetic sterols reported earlier [11]. Accordingly, 6 was assigned to be 24(S)-cholesta-5,25-diene-
3β,24-diol. 5 and 6 as stereoisomeric sterols were isolated from a natural origin for the first time. 
Table 2. 
13C NMR data of compounds 3–6 (CDCl3, 125 MHz) 
a. 
  3    4    5    6 
Position  C, mult.    C, mult.    C, mult.    C, mult. 
1  36.9 t    37.4 t    37.4 t    37.4 t 
2  31.6 t    31.8 t    31.8 t    31.8 t 
3  71.6 d    71.9 d    71.9 d    71.9 d 
4  42.5 t    42.5 t    42.4 t    42.4 t 
5  146.2 s    140.9 s    140.9 s    140.9 s 
6  120.9 d    121.8 d    121.8 d    121.9 d 
7  74.1 t    32.0 t    32.0 t    32.1 t 
8  37.3 d    32.1 d    32.0 d    32.1 d 
9  42.9 d    50.2 d    50.3 d    50.3 d 
10  37.6 s    36.6 s    36.7 s    36.7 s 
11  20.9 t    21.2 t    21.2 t    21.2 t 
12  39.2 t    39.8 t    39.9 t    39.9 t 
13  42.2 s    42.6 s    42.5 s    42.5 s 
14  49.2 d    56.8 d    56.9 d    56.9 d 
15  24.4 t    24.4 t    24.4 t    24.4 t 
16  28.8 t    28.5 t    28.3 t    28.4 t 
17  55.9 d    55.9 d    56.0 d    56.0 d 
18  11.6 q    12.0 q    12.0 q    12.0 q 
19  18.4 q    19.5 q    19.8 q    19.6 q 
20  36.0 d    36.0 d    35.7 d    35.7 d 
21  18.9 q    19.2 q    18.9 q    18.9 q 
22  36.3 t    39.5 t    31.8 t    31.8 t 
23  23.9 t    147.6 d    31.4 t    31.5 t 
24  39.7 t    132.8 d    76.9 d    76.5 d 
25  28.2 d    198.7 s    147.6 d    147.9 d 
26  22.7 q    27.1 q    111.5 t    111.0 t 
27  23.0 q    −    17.4 q    17.8 q 
7−OCH3  56.9 q    −    −    − 
a Assignments aided by the DEPT, COSY, TOCSY, HSQC, HMBC, and NOESY experiments. 
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Comparing their MS and NMR data with those reported in the literature, the known sterols were 
identified  as  (23Z)-cholesta-5,23-diene-3β,25-diol  (7)  [15],  cholest-5-ene-3β,7β-diol  (8)  [16],  
cholest-5-ene-3β,7ʱ-diol  (9)  [16],  (22E)-3β-hydroxy-24-norcholesta-5,22-dien-7-one  (10)  [16],  
(22E)-3β-hydroxycholesta-5,22-dien-7-one  (11)  [16],  3β-hydroxycholest-5-en-7-one  (12)  [16]  and 
(4E,22E)-12β-hydroxy-24-norcholesta-1,4,22-trien-3-one (13) [17], respectively. The cis-double bonds 
between C-23 and C-24, together with an oxygenated hydroxyl group at C-25 in the side chain of 7 is 
scarce  in  natural  sterols.  Sterols  8–12  were  previously  isolated  from  two  marine  sponges  Cliona 
copiosa [16] and Stelodoryx chlorophylla [18], and sterols 8–9 were also isolated from a soft coral 
Dendronephthya gigantean [19] and a marine bryozoan Biflustra grandicella [20]. Compound 13 was 
a highly functionalized C26 steroid Δ
1,4-dien-3-one with 12β oxygen function, which is a rare structural 
feature among sterols and has been isolated from soft coral Gersemia rubiformis [17]. However, all of 
the known sterols were isolated for the first time from this species. 
Compounds 1–4, 7 and 10–13 were evaluated for their cytotoxicity against HL-60 human myeloid 
leukemia cells in vitro, using a MTT assay method. The results of their cytotoxicity are shown in Table 
3. Although 12 and 13 did not show any apparent cytotoxicity, sterols 1–4, 7, 10 and 11 displayed 
moderate cytotoxicity to HL-60 cells with IC50 values of 17.91, 21.30, 22.11, 15.05, 18.28, 15.12 and 
14.73 g/mL, respectively. It appears that the cytotoxicity against HL-60 human myeloid leukemia 
cells of these sterols has a correlation with their structure. 
Table 3. Cytotoxic activities of compounds 1–4, 7 and 10–13 on HL-60 tumor cells 
a. 
Compound  IC50 (µg/mL)    Compound  IC50 (µg/mL) 
1  17.91    10  15.12 
2  21.30    11  14.73 
3  22.11    12  NA 
4  15.05    13  NA 
7  18.28    Adriamycin  2.50 
a IC50: 50% inhibitory concentration, HL-60: human myeloid leukemia cell line, NA: no activity. 
The present  chemical study of the marine bryozoan  C. pallasiana resulted in the isolation and 
characterization of six new sterols (1–6) and seven known sterols (7–13), four (3–6) of which have 
already been reported as synthetic sterols [9–11]. This is the first time that they (3–6) are reported as 
natural sterols. The structures of these new compounds are notable for the following viewpoints of 
natural product chemistry. Sterol 1, not reported previously in the literature, is characterized by an 
oxygenated methoxy group at C-25 in the side chain. In the nucleus of 2 and 3, the 7β methoxy group 
is a rare feature and first encountered among natural sterols. Compound 4 is specific in carbonylation 
at C-25 accompanied by a loss of a methyl group in the side chain. Sterols 5 and 6 are stereoisomeric 
with the C-24 with hydroxyl group in the side chain, which are reported as a natural source for the  
first time.  Mar. Drugs 2011, 9                                                  
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3. Experimental Section 
3.1. General Experimental Procedures 
Optical rotations  were measured on a Perkin-Elmer 343 polarimeter. 1D and 2D NMR spectra 
experiments  were  measured  in  CDCl3  on  a  Bruker  AVANCE-500  spectrometer,  with  TMS  as  an 
internal standard. Chemical shifts (ʴ) were expressed in ppm and coupling constants in Hz. EI-MS 
spectra were obtained on a MAT212 mass spectrometer; ESI-MS and HR-ESI-MS spectra were taken 
on a Micromass Quattro mass spectrometer. Separation and purification were performed by CC on 
silica  gel  H  (1040  m,  Qingdao  Marine  Chemical  Inc.,  Qingdao,  China),  Sephadex  LH-20 
(Pharmacia Inc., New Jersey, USA), reversed-phase Si gel (Lichroprep RP-18, 40–63 m, Merck Inc., 
Darmstadt, Germany). HPLC was carried out on a Dionex P680 liquid chromatograph equipped with a 
UV 170 UV/Vis detector at 206 nm using a YMC-Pack R﹠D ODS-A column (250  20 mm i.d.,  
5 m, YMC, Kyoto, Japan) for semi-preparation and a Thermo ODS-2 column (250  4.6 mm i.d.,  
5 m, Thermo Hypersi-Keystone Inc., Bellefonte, U.S.A.) for analysis. TLC detection was achieved by 
spraying  the  silica  gel  plates  (Qingdao  Marine  Chemical  Inc.,  Qingdao,  China)  with  20%  H2SO4 
followed by heating. 
3.2. Animal Material 
The samples of marine bryozoan Cryptosula pallasiana were collected in March 2009 from Huang 
Island,  Qingdao  City,  Shandong  Province  of  China,  and  were  identified  by  one  of  the  authors  
(Prof.  H.-W.  Lin).  A  voucher  specimen  (No:  QD-0903-1)  was  deposited  in  Marine  Laboratory, 
Changzheng Hospital, Second Military Medical University. 
3.3. Extraction and Isolation 
Fresh samples of Cryptosula pallasiana (about 20 kg) were extracted with 95% EtOH at ambient 
temperature. The concentrated aqueous  solution  was  extracted with  EtOAc.  Then,  the extract  was 
partitioned between 90% aqueous MeOH and petroleum ether. The MeOH solution was adjusted to 
80% aqueous MeOH and extracted with CCl4. The CCl4 fraction (12.9 g) was subjected to column 
chromatography (CC) on Sephadex LH-20 with CHCl3/MeOH (1:1) as eluting solvent to afford three 
fractions (Frs. AC) based on TLC analysis (developed by petroleum ether/EtOH, 5:1). Fr. A (5.66 g) 
was subjected to CC on reversed-phase silica gel column eluting with MeOH/H2O (80:20 to 100:0) 
gradient to give two major fractions A1 (2.44 g) and A2 (3.18 g). Fr. A2 was submitted to CC over silica 
gel eluting with petroleum ether/EtOAc (15:1, 10:1, 5:1, 1:1) gradient to give 12 major fractions (Frs. 
A2-1A2-12). Fr. A2-7 (238.9 mg) was eluted with CHCl3/MeOH (1:1) on Sephadex LH-20 and then 
further  purified  by  semi-preparative  HPLC  to  afford  1  (6.0  mg,  tR  =  97.7  min),  5  (12.0  mg, 
 tR = 34.0 min), 6 (11.2 mg, tR = 35.6 min) and 7 (11.4 mg, tR = 38.4 min), using MeOH/H2O (87:13) 
as the mobile phase at a flow rate of 8.0 mL/min. Fr. A2-6 was purified by semi-preparative HPLC 
(MeOH/H2O  90:10,  flow  rate  of  8.0  mL/min)  to  yield  2  (3.5  mg,  tR  =  40.7  min),  3  (10.5  mg,  
tR  =  50.5  min)  and  4  (2.0  mg,  tR  =  16.8  min).  Fr.  A2-9  (577.0  mg)  was  firstly  purified  by  
semi-preparative  HPLC  (MeOH/H2O  90:10,  flow  rate  of  8.0  mL/min)  to  give  12  fractions  Mar. Drugs 2011, 9                                                  
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(Frs. A2-9-1A2-9-12), and then the Fr. A2-9-12 (47.4 mg) was further purified by analytic HPLC to 
afford 8 (14.8 mg, tR = 32.1 min) and 9 (18.2 mg, tR = 35.4 min), using MeOH/H2O (87:13) as the 
mobile phase at a flow rate of 1.0 mL/min. Fr. A2-8 (147.5 mg) was eluted with CHCl3/MeOH (1:1) on 
Sephadex  LH-20  and  then  further  purified  by  semi-preparative  HPLC  to  give  10  (3.4  mg,  
tR = 71.8 min), 11 (4.1 mg, tR = 98.3 min) and 12 (8.9 mg, tR = 130.5 min), 13 (4.0 mg, tR = 36.5 min), 
using MeOH/H2O (90:10) as the mobile phase at a flow rate of 8.0 mL/min.  
3.3.1. Liebermann-Burchard Test 
Each sample (1–2 mg) was dissolved in a mixture of 2 mL CHCl3 and anhydrous acetic acid (1:1), 
then a few drops of concentrated sulfuric acid was added and mixed cautiously. The appearance of a 
green color indicated the presence of sterol. 
3.3.2. (23E)-25-Methoxy-cholesta-5,23-dien-3β-ol (1) 
White amorphous powder; []
22
D − 40.7 (c 0.05, CHCl3); 
1H NMR and 
13C NMR data, see Table 1; 
EI-MS m/z: 414 [M]
+ (16), 399 [M − CH3]
+ (100), 382 [M − OCH3 − H]
+ (26), 367 (18), 349 (11), 301 
[M − C6H10OCH3]
+ (25), 300 (30), 283 [M − C6H10OCH3 − H2O]
+ (37), 271 (46), 241 (12), 227 (10), 
215 (24), 183 (19), 159 (27), 133 (31), 113 [C6H10OCH3]
+ (28), 99 (47), 85 (61), 55 (42); HR-ESI-MS 
(positive) m/z: 437.3398 [M + Na]
+ (C28H46O2Na, calcd. for 437.3396). 
3.3.3. (22E)-7β-Methoxy-cholesta-5,22-dien-3β-ol (2) 
White amorphous powder; []
22
D − 67.5 (c 0.05, CHCl3); 
1H NMR and 
13C NMR data, see Table 1; 
EI-MS m/z: 414 [M]
+ (38), 396 [M − H2O]
+ (42), 382 [M − OCH3 − H]
+ (100), 367 (8), 349 (12), 303 
[M − C8H15]
+ (10), 298 (15), 271 [M − C8H15 − OCH3 − H]
+ (22), 253 (21), 211 (13), 197 (9), 175 (14), 
159 (17), 145 (19), 135 (17), 119 (16), 111 [C8H15]
+ (22), 69 (30), 55 (37); HR-ESI-MS (positive) m/z: 
437.3394 [M + Na]
+ (C28H46O2Na, calcd. for 437.3396). 
3.3.4. 7β-Methoxy-cholest-5-en-3β-ol (3) 
White amorphous powder; []
22
D − 72.4 (c 0.10, CHCl3); 
1H NMR (500 MHz, CDCl3) ʴ: 0.66 (3H, s, 
H3-18), 0.86 (3H, d, J = 2.3 Hz, H3-27), 0.87 (3H, d, J = 2.3 Hz, H3-26), 0.91 (3H, d, J = 6.5 Hz,  
H3-21), 0.98 (3H, s, H3-19), 2.34 (1H, m, Hʱ-4), 2.29 (1H, m, Hβ-4), 3.29 (1H, t, J = 3.3 Hz, H-7), 3.36 
(3H, s, H3-7−OCH3), 3.62 (1H, m, H-3), 5.73 (1H, dd, J = 4.9, 1.6 Hz, H-6); 
13C NMR data, see Table 
2; EI-MS m/z: 416 [M]
+ (26), 398 [M − H2O]
+ (37), 384 [M − OCH3 − H]
+ (100), 369  (11), 351 (12), 
271 [M − C8H17 − OCH3 − H]
+ (7), 253 (5), 213 (6), 211 (7), 185 (5), 175 (9),159 (12), 145 (12), 119 
(12), 95 (15), 81 (14), 69 (11), 55 (15); HR-ESI-MS (positive) m/z: 439.3550 [M + Na]
+ (C28H48O2Na, 
calcd. 439.3552). 
3.3.5. (23E)-3β-Hydroxy-27-norcholesta-5,23-dien-25-one (4) 
White amorphous powder; []
22
D − 46.7 (c 0.02, CHCl3); 
1H NMR (500 MHz, CDCl3) ʴ: 0.70 (3H, s, 
H3-18), 0.95 (3H, d, J = 6.6 Hz, H3-21), 1.01 (3H, s, H3-19), 2.25 (3H, s, H3-26), 3.52 (1H, m, H-3), Mar. Drugs 2011, 9                                                  
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5.35 (1H, t, J = 2.8 Hz, H-6), 6.07 (1H, d, J = 15.5 Hz, H-24 ), 6.78 (1H, m, H-23); 
13C NMR data, see 
Table 2; EI-MS m/z: 384 [M]
+ (100), 366 [M − H2O]
+ (66), 351 [M − CH3 − H2O]
+ (40), 324 (9), 299 
(29), 283 (32), 273 [M − Side Chain]
+ (41), 255 [M − H2O − Side Chain]
+ (23), 213 (45), 199 (19), 
189  (29),  173  (24),  159  (48),  145  (54),  133  (44),  119  (46),  107  (62),  95  (52),  81  (54),  67  (38);  
HR-ESI-MS (positive) m/z: 407.2928 [M + Na]
+ (C26H40O2Na, calcd. for 407.2926) 
3.3.6. 24(R)-Cholesta-5,25-diene-3β,24-diol (5) 
White amorphous powder; []
22
D − 19.4 (c 0.10, CHCl3); 
1H NMR (500 MHz, CDCl3) ʴ: 0.68 (3H, s, 
H3-18), 0.93 (3H, d, J = 6.6 Hz, H3-21), 1.00 (3H, s, H3-19), 1.72 (3H, s, H3-27), 3.52 (1H, m, H-3), 
4.00 (1H, t, J = 6.6 Hz, H-24), 4.83 (1H, t, J = 1.4 Hz, Ha-26), 4.92 (1H, s, Hb-26), 5.35 (1H, d, J = 5.2 
Hz, H-6); 
13C NMR data, see Table 2; EI-MS m/z: 400 [M]
+ (41), 382 [M − H2O]
+ (56), 367 [M − CH3 
− H2O]
+ (33), 349 (25), 340 (10), 328 (13), 315 (22), 300 [M − C6H10 − H2O]
+ (27), 271 [M − C8H15 − 
H2O]
+ (100), 255 (36), 243 (17), 229 (31), 213 (46), 199 (23), 187 (26), 173 (30), 161 (49), 145 (52), 
133 (46), 119 (46), 107 (58), 95 (56), 81 (60), 71 (65), 55 (63); HR-ESI-MS (positive) m/z: 423.3241 
[M + Na]
+ (C27H44O2Na, calcd. for 423.3239). 
3.3.7. 24(S)-Cholesta-5,25-diene-3β,24-diol (6) 
White amorphous powder, []
22
D − 27.9 (c 0.10, CHCl3); 
1H NMR (500 MHz, CDCl3) ʴ: 0.68 (3H, s, 
H3-18), 0.93 (3H, d, J = 6.6 Hz, H3-21), 1.00 (3H, s, H3-19), 1.72 (3H, s, H3-27), 3.52 (1H, m, H-3), 
4.00 (1H, t, J = 6.4 Hz, H-24), 4.83 (1H, t, J = 1.4 Hz, Ha-26), 4.93 (1H, s, Hb-26), 5.35 (1H, d, J = 5.3 
Hz, H-6); 
13C NMR data, see Table 2; EI-MS m/z: 400 [M]
+ (41), other ion fragments identical with 5; 
HR-ESI-MS (positive) m/z: 423.3237 [M + Na]
+ (C27H44O2Na, calcd. for 423.3239). 
3.4. MTT Cytotoxicity Assays 
The cytotoxicity of compounds 1–4, 7 and 10–13 were evaluated against HL-60 cancer cell line by 
microculture tetrazolium (MTT) assay [21]. The cells were obtained from American Type Culture 
Collection (ATCC), and maintained in RPMI 1640 medium (Gibco, Invitrogen Co., USA) containing 
10% fetal bovine serum (Gibco, Invitrogen Co., USA) supplemented with 100 U/mL penicillin, and 
100 U/mL streptomycin. The leukemia cells were washed and re-suspended in the above medium to  
1 ×  10
5 cells/mL. 2 mL of this cell suspension was placed into 96-well microculture plates and allowed 
to adhere in 5% CO2/air for 24 h at 37 ° C before drug addition. 20 µL of DMSO solution containing 
the sample was added to give the various concentrations in triplicate for 72 h, with adriamycin (Sigma) 
as positive control. After the incubation, 20 µL of MTT solution (5 mg/mL) was added to each well, 
and the incubation continued for 4 h at 37 ° C. Then, 150 µL of DMSO solution was added to each 
well, and the formazan crystals in each well were dissolved by stirring with a pipette. The optical 
density (OD) was read on a plate reader on an ELISA reader (MK3, USA) at a wavelength of 570 nm. 
Each  assay  was  done  in  triplicate,  and  inhibition  was  expressed  as  IC50  value,  which  stands  for 
inhibition of cell growth by 50%. Mar. Drugs 2011, 9                                                  
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